Boundless Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Boundless Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.0 times its market value (net cash). Higher than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-41.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 69% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-14.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
1.0× cashCash, after subtracting all debt, is 1.0 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Boundless Bio, Inc. made a loss over the last year. Boundless Bio, Inc. owes $0.11 for every $1 it owns. Boundless Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBoundless Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.83The share price is 0.83 times Boundless Bio, Inc.'s book value per share, lower than 83% of Healthcare companies in United States.
Market cap
$55 MThe total market value of all of Boundless Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$66 MWhat Boundless Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.85Net worth divided by the number of shares. The share price of $2.36 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-67.9%Boundless Bio, Inc. lost 67.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
Owes vs Owns
0.11×Boundless Bio, Inc. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Dividend yield
NoneBoundless Bio, Inc. does not currently pay a dividend.
Profit growth
LossBoundless Bio, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashBoundless Bio, Inc. held $59 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Boundless Bio, Inc.: $55 M ÷ $66 M (30 Jun 2026) = 0.8.
What is Boundless Bio, Inc.'s return on equity?
Boundless Bio, Inc. lost 67.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
How much does Boundless Bio, Inc. owe compared with what it owns?
Boundless Bio, Inc. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Does Boundless Bio, Inc. pay a dividend?
No. Boundless Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.